Paxmedica achieves key milestone in the development of pax-101 and provides update on potential nda submission

Tarrytown, new york, april 11, 2024 (globe newswire) -- via ibn – paxmedica , inc. (nasdaq: pxmd ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of pax-101, an iv formulation of suramin. this achievement is an important milestone to enabling a new drug application (nda) submission to the u.s. food and drug administration (fda), which is currently planned for q4 2024, and for the potential commercial availability in the u.s. of the first and only form of suramin for the treatment of stage 1 human african trypanosomiasis (hat), caused by trypanosoma brucei rhodesiense, a fatal, neglected tropical disease, if approved by the fda.
PXMD Ratings Summary
PXMD Quant Ranking